Tevard Biosciences, Inc., The Pioneer Of Trna-Based Therapies For Severe Genetic Diseases, Announced A Four-Year Global Research Collaboration With Vertex Pharmaceuticals Incorporated Aimed At Creating New Trna-Based Therapies For Patients With Duchenne Muscular Dystrophy (Dmd) Caused By Nonsense Mutations With Options To Expand Into Additional Muscular Dystrophies And A Second Indication.The Agreement Provides Access To Tevard
